Advances and Perspectives in Urinary Bladder Cancer Nanotherapy-Reference-Cited by-同舟云学术

Advances and Perspectives in Urinary Bladder Cancer Nanotherapy

Published:2018-05-08 Issue: Volume: Page:52-61
ISSN:2053-4213
Container-title:EMJ Urology
language:en
Short-container-title:EMJ Urol

Author:

da Silva Rogério C.¹,de Souza Joel G.¹,Seabra Amedea B.²,Durán Nelson³,Fávaro Wagner J.⁴

Affiliation:

1. Laboratory of Urogenital Carcinogenesis and Immunotherapy, Department of Structural and Functional Biology, Universidade Estadual de Campinas, Campinas, Brazil

2. Center for Natural and Human Sciences, Universidade Federal do ABC, São Paulo, Brazil; Nanomedicine Research Unit (Nanomed), Federal University of ABC (UFABC), São Paulo, Brazil; NanoBioss, Institute of Chemistry, Universidade Estadual de Campinas, Campinas, Brazil

3. Center for Natural and Human Sciences, Universidade Federal do ABC, São Paulo, Brazil; Nanomedicine Research Unit (Nanomed), Federal University of ABC (UFABC), São Paulo, Brazil; NanoBioss, Institute of Chemistry, Universidade Estadual de Campinas, Campinas, Brazil; Institute of Chemistry, BiolChemLab., Universidade Estadual de Campinas, Campinas, Brazil

4. Laboratory of Urogenital Carcinogenesis and Immunotherapy, Department of Structural and Functional Biology, Universidade Estadual de Campinas, Campinas, Brazil; NanoBioss, Institute of Chemistry, Universidade Estadual de Campinas, Campinas, Brazil

Abstract

Bladder cancer treatment remains a challenge in the pharmaceutical field due to the recurrence and progression of the disease, as well as the pronounced side effects associated with the available therapeutic modalities. Although important strategies have been investigated in different clinical trial phases, efficient and well-tolerated treatment approaches need to be developed to improve therapeutic efficacy and the quality of life for bladder cancer patients. This review discusses conventional protocols used in the clinical setting, detailing the use of Bacillus Calmette–Guérin, new immunomodulators, and drug delivery systems. New therapeutic approaches have been investigated with the aim of better therapeutic efficacy with low rates of recurrence and progression of non-muscle invasive bladder cancer and muscle invasive bladder cancer. Therefore, this review highlights the progression of therapy with the use of conventional treatments and the recent progress achieved from the use of innovative strategies, such as nanoparticles for sustained, controlled drug delivery and increased drug uptake by tumour cells.

Publisher

European Medical Group

Subject

General Medicine

Reference64 articles.

1. Witjes JA et al. Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462-75.

2. Babjuk M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 2017;71(3):447-61.

3. Siegel RL et al. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.

4. Martin DT et al. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine. 2013;9(8):1124-34.

5. Lamm L et al. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol. 2014;32(1):e21-30.